Xilio Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 42.00 shares, a 99.41% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 109.00 shares, a 98.83% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was -16.19K shares, a 1143.91% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 1.10K shares, a 82.07% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.34K shares, a 84.68% decline from fiscal 2024.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 8.77K shares, a 217.95% increase from fiscal 2023.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 2.76K shares, a 3.76% increase from fiscal 2022.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 2.66K shares, a 94.45% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 42.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -14.94K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 109.00 shares 10-Q · filed 2026-05-12 | -7.84K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | -16.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 1.34K shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 1.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 19.09K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 7.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 24.13K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 9.29K shares 10-Q · filed 2025-05-08 | |
| 2024-12-31 | 1.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 8.77K shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 6.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 2.76K shares 10-K · filed 2024-04-01 |
| 2023-09-30 | 2.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.76K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 168.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 324.00 shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 156.00 shares 10-Q · filed 2023-05-09 | 156.00 shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 2.66K shares 10-K · filed 2023-03-02 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 42.47K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | |
| 2022-03-31 | 2.66K shares 10-Q · filed 2022-05-12 | |
| 2021-12-31 | 39.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 47.90K shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |